BR112015014875A2 - composição farmacêutica que contém candesartana cilexetila e anlodipina - Google Patents

composição farmacêutica que contém candesartana cilexetila e anlodipina

Info

Publication number
BR112015014875A2
BR112015014875A2 BR112015014875A BR112015014875A BR112015014875A2 BR 112015014875 A2 BR112015014875 A2 BR 112015014875A2 BR 112015014875 A BR112015014875 A BR 112015014875A BR 112015014875 A BR112015014875 A BR 112015014875A BR 112015014875 A2 BR112015014875 A2 BR 112015014875A2
Authority
BR
Brazil
Prior art keywords
candesartan cilexetil
amlodipine
composition
pharmaceutical composition
composition containing
Prior art date
Application number
BR112015014875A
Other languages
English (en)
Inventor
Cieplucha Agnieszka
Original Assignee
Adamed Sp Zo O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015014875(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Sp Zo O filed Critical Adamed Sp Zo O
Publication of BR112015014875A2 publication Critical patent/BR112015014875A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

1/1 resumo composição farmacêutica que contém candesartana cilexetila e anlodipina uma composição farmacêutica combinada que compreende candesartana cilexetila e anlodipina ou um sal desse aceito farmaceuticamente, um processo para a preparação de uma dita composição e forma de unidade de dosagem que compreende uma dita composição. a composição consiste de um granulado que contém candesartana cilexetila, glicol de polietileno e outros excipientes, em que a razão de peso de candesartana cilexetila para glicol de polietileno está na faixa a partir de 5:1 até 2:1, e a fase extragranular de mistura de pó que compreende anlodipina ou um sal desse aceito farmaceuticamente e excipientes. uma composição é preparada misturando o granulado preparado pela granulação úmida e pela fase extragranular.
BR112015014875A 2012-12-21 2013-12-19 composição farmacêutica que contém candesartana cilexetila e anlodipina BR112015014875A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL402191A PL236001B1 (pl) 2012-12-21 2012-12-21 Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
PCT/IB2013/061138 WO2014097209A1 (en) 2012-12-21 2013-12-19 A pharmaceutical composition containing candesartan cilexetil and amlodipine

Publications (1)

Publication Number Publication Date
BR112015014875A2 true BR112015014875A2 (pt) 2017-07-11

Family

ID=50030379

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014875A BR112015014875A2 (pt) 2012-12-21 2013-12-19 composição farmacêutica que contém candesartana cilexetila e anlodipina

Country Status (19)

Country Link
EP (1) EP2934488B1 (pt)
AU (1) AU2013365715B2 (pt)
BR (1) BR112015014875A2 (pt)
EA (1) EA030704B1 (pt)
ES (1) ES2706067T3 (pt)
HK (1) HK1213808A1 (pt)
HR (1) HRP20190049T1 (pt)
HU (1) HUE042194T2 (pt)
MX (1) MX2015008032A (pt)
MY (1) MY185947A (pt)
PH (1) PH12015501301A1 (pt)
PL (2) PL236001B1 (pt)
PT (1) PT2934488T (pt)
RS (1) RS58214B1 (pt)
SG (1) SG11201504473XA (pt)
TR (1) TR201900350T4 (pt)
UA (1) UA115257C2 (pt)
WO (1) WO2014097209A1 (pt)
ZA (1) ZA201505192B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3236950T1 (sl) * 2014-12-24 2023-04-28 Krka, D.D., Novo Mesto Farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive soli ali estre in amlodipin ali njegove farmacevtsko sprejemljive soli
CN104721159A (zh) * 2015-03-24 2015-06-24 浙江康乐药业股份有限公司 一种苯磺酸氨氯地平片及其制备方法
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (pt) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
PL189666B1 (pl) 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
WO2004075825A2 (en) 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Dosage forms of amlodipine and processes for their preparation
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
WO2008134013A2 (en) 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical excipient complex
EP2050440A1 (en) 2007-10-18 2009-04-22 Krka Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof
EP2106789A1 (en) * 2008-03-31 2009-10-07 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising candesartan
SI2165702T1 (sl) 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
BRPI1014388A2 (pt) 2009-04-30 2016-04-05 Takeda Pharmaceutical preparação de sólido.
CN101966181A (zh) * 2010-07-08 2011-02-09 王丽燕 包含坎地沙坦和氨氯地平的口服固体制剂及其新应用
CN102743381B (zh) * 2011-04-22 2014-08-27 重庆市力扬医药开发有限公司 一种稳定的坎地沙坦酯氨氯地平药物组合物及其制备方法
CN102764258B (zh) 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种坎地沙坦酯氨氯地平复方片的制备方法
CN102670603B (zh) * 2012-04-29 2017-10-31 浙江华海药业股份有限公司 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法

Also Published As

Publication number Publication date
EA201591097A1 (ru) 2015-10-30
PL402191A1 (pl) 2014-06-23
EP2934488A1 (en) 2015-10-28
HUE042194T2 (hu) 2019-06-28
HK1213808A1 (zh) 2016-07-15
PH12015501301B1 (en) 2015-08-24
PL236001B1 (pl) 2020-11-30
WO2014097209A1 (en) 2014-06-26
AU2013365715B2 (en) 2017-10-05
PH12015501301A1 (en) 2015-08-24
PL2934488T3 (pl) 2019-04-30
UA115257C2 (uk) 2017-10-10
PT2934488T (pt) 2019-01-29
SG11201504473XA (en) 2015-07-30
AU2013365715A1 (en) 2015-06-18
EP2934488B1 (en) 2018-10-17
RS58214B1 (sr) 2019-03-29
MX2015008032A (es) 2015-10-30
ES2706067T3 (es) 2019-03-27
TR201900350T4 (tr) 2019-02-21
MY185947A (en) 2021-06-14
EA030704B1 (ru) 2018-09-28
HRP20190049T1 (hr) 2019-02-22
ZA201505192B (en) 2016-07-27

Similar Documents

Publication Publication Date Title
BR112015014875A2 (pt) composição farmacêutica que contém candesartana cilexetila e anlodipina
HRP20201685T1 (hr) Sastavi gama-hidroksibutirata i njihova upotreba za liječenje poremećaja
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
BRPI0919753B8 (pt) forma polimórfica de palmitoiletanolamida, composição farmacêutica para uso humano ou veterinário, método para a micronização da palmitoiletanolamida e palmitoiletanolamida ultramicronizada
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
EA201300053A1 (ru) Фосфатсвязывающий препарат для удобного приема
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
CL2013002166A1 (es) Compuesto correspondiente a la sal de magnesio del acido (s)-alfa-etoxi-4-[2-metil-5-[4-metiltiofenil-1h-pirrol-1-il]etoxi]bencenpropanoico; composicion farmaceutica que lo comprende; y uso para el tratamiento de lipodistrofia.
IN2014MN01919A (pt)
CL2011002130A1 (es) Uso de una composicion que comprende una mezcla fisica o combinacion de polvos, granulos, cristales o agregados de sales de calcio, magnecio y hierro para el tratamiento de enfermedades relacionadas con la absorcion alterada de fosforo en seres humanos y animales.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
BR112015004523A2 (pt) compostos de tetraciclina
BRPI0823302A2 (pt) Composição farmacêutica que contém um derivado de n-fenilpirazol, utilização para a preparação de um medicamento veterinário tópico para lutar contra as pulgas
BR112012026714A2 (pt) pastilhas de eritritol e isomalte
BR112015012111A8 (pt) formulações de mistura de pó direta, soluções orais, e usos de um fármaco para preparação das mesmas.
BRPI1016064A2 (pt) "formulação com compartimentos múltiplos, processo para a preparação da mesma, agentes de transporte ou de vetorização, e de liberação intracelular de agentes terapêuticos, utilização de uma formulação, e composição farmacêutica"
BR112012023281A2 (pt) composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
BR112012030485A2 (pt) composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma
BR112015022398A8 (pt) comprimido de ondansetrona e preparação farmacêutica embalada
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
BR112012018135A2 (pt) preparação farmacêutica, e, método para fabricar a preparação farmacêutica
BR112015014839A2 (pt) forma cristalina do composto utilizado como antagonista do receptor de mineralocorticóide e método para a sua preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI